Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Second Prospective Cohort of Patients Entering the Multidisciplinary Care Pathway for Post-Covid Syndromes - SyPoCo2 Cohort

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The study aims to identify clinical profiles of long-COVID patients and correlate them with immunological and molecular data in order to identify prognostic biomarkers and potential therapeutic targets.

Who May Be Eligible (Plain English)

Who May Qualify: - Documented SARS-CoV-2 infection - Persistent or complex post-COVID symptoms lasting more than 4 weeks or more than 3 months - Patient referred to the EPSILON pathway or to the post-COVID rehabilitation unit - Age ≥ 18 years - Non-institutionalized - Expected survival greater than 6 months Who Should NOT Join This Trial: - Refusal to participate or to share data - Uncontrolled comorbidities - Pregnant or breastfeeding women - Persons under legal protection or deprived of liberty - Not affiliated with the French national health insurance system Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Documented SARS-CoV-2 infection * Persistent or complex post-COVID symptoms lasting more than 4 weeks or more than 3 months * Patient referred to the EPSILON pathway or to the post-COVID rehabilitation unit * Age ≥ 18 years * Non-institutionalized * Expected survival greater than 6 months Exclusion Criteria: * Refusal to participate or to share data * Uncontrolled comorbidities * Pregnant or breastfeeding women * Persons under legal protection or deprived of liberty * Not affiliated with the French national health insurance system

Treatments Being Tested

OTHER

Blood sample collection

A one-time 30 mL blood draw is performed during the inclusion visit for immunological and molecular analysis as part of the HERVCOV research program. No therapeutic intervention is administered, and no samples are stored after analysis.

Locations (2)

Service Pneumologie aigue spécialisée et cancérologie thoracique
Pierre-Bénite, France
Hôpital Henry Gabrielle-HCL
Saint-Genis-Laval, France